3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
24
Neoplasm Metastasis
8
Leukemia, Myeloid, Acute
8
Carcinoma, Renal Cell
7
Ovarian Neoplasms
6
Lymphoma, Non-Hodgkin
6
Carcinoma, Non-Small-Cell Lung
6
Stomach Neoplasms
5
Colorectal Neoplasms
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Neuroblastoma
4
Neoplasms
4
Lymphoma
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Esophageal Neoplasms
3
Colonic Neoplasms
3
Uveal Melanoma
2
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Rectal Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Multiple Myeloma
2
Mesothelioma, Malignant
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Interventions
pembrolizumab
3
Nivolumab
2
sintilimab
1
regorafenib
1
denileukin diftitox
1
Radiation Dose Hypofractionation
1
Ipilimumab
1
Interleukin-2
1
Immune Checkpoint Inhibitors
1
E7777 fusion protein
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Turcot syndrome
×
Interleukin-2
×
Clear all
NCT05086692
2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2
Recruiting
115 enrolled